skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
HLA-A*2402-Restricted CDCA1-A24-56 Peptide Vaccine (Code C94223)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: HLA-A*2402-Restricted CDCA1-A24-56 Peptide Vaccine

Definition: A cancer vaccine containing the HLA-A*2402-restricted peptide epitope derived from cell division associated gene 1 (CDCA1), with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*2402-restricted CDCA1-A24-56 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against CDCA1-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.

Label: HLA-A*2402-Restricted CDCA1-A24-56 Peptide Vaccine

NCI Thesaurus Code: C94223 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL426035  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HLA-A*2402-Restricted CDCA1-A24-56 Peptide Vaccine
HLA-A*2402-Restricted Cell Division Cycle Associated 1-A24-56 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 687974
PDQ Open Trial Search ID 687974 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C94223
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom